Phesi’s annual global analysis of 67,469 recruiting clinical trials shows that breast cancer is the world’s most studied disease for the fourth year running. The data reveals one in three clinical trials were terminated during Phase II, a 50% increase from pre-COVID 19 levels. This represents tens of millions of dollars that could be saved by using data science, AI and clinical data analytics to deliver greater precision in trial design and execution.
Leveraging global data from more than 132 million patients, Trial Accelerator™ generates a detailed picture of the patient for any indication, ensuring greater precision in trial design and execution.
